Cerliponase alfa - BioMarin Pharmaceutical

Drug Profile

Cerliponase alfa - BioMarin Pharmaceutical

Alternative Names: BMN 190; Brineura; rhTPP1

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Enzymes; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Tripeptidyl peptidase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuronal ceroid lipofuscinosis

Most Recent Events

  • 02 Aug 2017 Launched for Neuronal ceroid lipofuscinosis (In adolescents, In children) in Argentina prior to August 2017 (Intracerebral)
  • 02 Aug 2017 Launched for Neuronal ceroid lipofuscinosis (In adolescents, In children) in France prior to August 2017 (Intracerebral)
  • 02 Aug 2017 Launched for Neuronal ceroid lipofuscinosis (In adolescents, In children) in Germany prior to August 2017 (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top